|
Age at menopause
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Primary biliary cirrhosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study identifies six novel risk loci for primary biliary cholangitis.
|
28425483 |
2017 |
|
Reticulocyte count (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Age at menopause
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair.
|
26414677 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the BRIGHT AML 1003 study, glasdegib in combination with low-dose cytarabine (LDAC) was well tolerated and demonstrated a significant 54% reduction in mortality compared with LDAC for AML patients.
|
31432695 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
Biomarker
|
disease |
BEFREE |
Evidence of clinical benefit came from Study BRIGHT AML 1003, a randomized trial comparing glasdegib+LDAC with LDAC alone for treatment of newly diagnosed AML in 115 patients either ≥ 75 years old or ≥ 55 years old with preexisting comorbidities.
|
31064779 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
Biomarker
|
disease |
BEFREE |
BRIGHT AML 1019 (NCT03416179) comprises two independently powered Phase III, randomized (1:1), double-blind global trials evaluating oral glasdegib 100 mg once daily or placebo plus one of two standard chemotherapy regimens in adults with untreated AML.
|
31516032 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
These data identify ARID3a as a potential transcription regulator of IFNα-related inflammatory responses and other pathways important for SLE disease activity.
|
30297159 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The associations of ARID3a expression with increased disease severity in SLE, suggest that it, or its downstream targets, may provide new therapeutic targets for SLE.
|
31554207 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.030 |
Biomarker
|
disease |
BEFREE |
SLE HSPCs with high numbers of ARID3a(+) cells also more readily generated autoantibody-producing cells than HSPCs with lower levels of ARID3a in a humanized mouse model.
|
25535283 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
BRIGHT was a multicentre, open-label, randomized, active-controlled, 2-arm, parallel-group, 24-week study in insulin-naïve patients with uncontrolled type 2 diabetes initiated on Gla-300 (N=466) or IDeg-100 (N=463).
|
31646724 |
2020 |
|
Malignant tumor of colon
|
0.020 |
Biomarker
|
disease |
BEFREE |
Recent studies have shown a marked increase of AT-rich interactive domain 3A (ARID3A) in colon cancer tissue compared to normal colon mucosa.
|
31177122 |
2019 |
|
Rectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We, therefore, investigated the clinical relevance of ARID3A expression in patients with residual rectal cancer after neoadjuvant chemoradiotherapy (NACRT).
|
31177122 |
2019 |
|
Encephalitis, St. Louis
|
0.020 |
Biomarker
|
disease |
BEFREE |
New Frontiers: ARID3a in SLE.
|
31554207 |
2019 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Recent studies have shown a marked increase of AT-rich interactive domain 3A (ARID3A) in colon cancer tissue compared to normal colon mucosa.
|
31177122 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
ARID3A positivity was found in 91 cases (64.5%), and it correlated with absence of perineural invasion (p=0.031), longer disease-free survival (DFS) (p=0.048) and cancer-specific survival (CSS) (p=0.006).
|
31177122 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
BRIGHT (NCT02738151) was a multicenter, open-label, active-controlled, two-arm, parallel-group, 24-week, noninferiority study in insulin-naive patients with uncontrolled type 2 diabetes.
|
30104294 |
2018 |
|
Encephalitis, St. Louis
|
0.020 |
Biomarker
|
disease |
BEFREE |
SLE HSPCs with high numbers of ARID3a(+) cells also more readily generated autoantibody-producing cells than HSPCs with lower levels of ARID3a in a humanized mouse model.
|
25535283 |
2015 |
|
Malignant tumor of colon
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In doing so, a favorable prognostic effect of ARID3A expression was revealed only in the colon cancer group (p = 0.002), not in rectal cancer.
|
24366420 |
2014 |
|
Rectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In doing so, a favorable prognostic effect of ARID3A expression was revealed only in the colon cancer group (p = 0.002), not in rectal cancer.
|
24366420 |
2014 |
|
Colon Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In doing so, a favorable prognostic effect of ARID3A expression was revealed only in the colon cancer group (p = 0.002), not in rectal cancer.
|
24366420 |
2014 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
ARID3A expression in CRC was significantly correlated with age, degree of differentiation, depth of invasion, lymph node metastasis, distant metastasis, tumor-node-metastasis stage, status of microsatellite instability, and carcinoembryonic antigen levels.
|
24366420 |
2014 |
|
Hypertensive disease
|
0.020 |
GeneticVariation
|
group |
BEFREE |
A non-significant trend for association was also detected with severe family based hypertension in the BRIGHT sample (British).
|
19304780 |
2009 |
|
Hypertensive disease
|
0.020 |
GeneticVariation
|
group |
BEFREE |
To assess if INPPL1 variants play a direct role in the development of essential hypertension, we genotyped the three previously associated INPPL1 polymorphisms in a cohort of 712 families with severe hypertension from the BRIGHT study transmission disequilibrium test cohort.
|
17557929 |
2007 |
|
Congestive heart failure
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The present study was a subanalysis of the BRIGHT-D study that focused on the effects of bisoprolol vs carvedilol on inflammation and oxidative stress in CHF patients.
|
31444140 |
2020 |